First biosimilar medication in Latin America developed in Rio de Janeiro

  • Português
  • English
  • Posted on December 9, 2015


    Rio de Janeiro celebrates the development of the first biosimilar medication in Latin America. Developed by Eurofarma, Fiprima (filgrastim) is vital for patients going through chemotherapy treatments and because of that present a a very low neuthophil count, meaning the white blood cells that help fight infections. Worldwide, there are only 20 registered biosimilars, including the Brazilian product, considered by specialists a new frontier for the global pharmaceutical industry.

    Fiprima will be produced by the Oswaldo Cruz Foundation (Fiocruz), through a technology exchange agreement, and distributed for free through the Single Health System (SUS). By producing it themselves, the Ministry of Health intends to save approximately R$ 9,3 million in five years. The medication, approved a little over a month ago by the National Health and Safety Agency (Anvisa), should reach the market next year. The development of the Brazilian biosimilar was the result of 10 years of research and R$ 12 million in financing.

    Rio Negócios Newsletter

    Cadastre-se e receba mensalmente as principais novidades em seu email

    Quero receber o Newsletter